The Data Safety Monitoring/Quality Assurance Committee (DSM/QAC) ensures the safety of patients who are subjects in clinical research at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC). UMGCC's DSM/QAC reviews in an ongoing fashion Severe Adverse Events (SAEs), internal and external, to define whether expedited reporting to the Institutional Review Board (IRB) ofthe University of Maryland School of Medicine (UMSOM) and/or altering informed consent is warranted. UMGCC's DSM/QAC is recognized by IRB as the DSM body of record for UMGCC protocols that do not have a freestanding, independent DSM process. DSM/QAC reviews in that capacity the following types of protocols: investigator-initiated trials of any phase, all Phase I trials irrespective of sponsor, and NCI-sponsored or corporate Phase II trials for which an independent DSM committee is not active. On at least an annual basis, this entails reviewing the currency and accuracy of the consent form, the protocol regulatory binder, response rates, audit results, and whether accrual during the review period is within the allowed enrollment according to the latest IRB review. DSM/QAC will review audits contracted to and performed by UMSOM's IRB of 50 percent of patients accrued to the protocol types under its purview. DSM/QAC may also direct its own audits, as necessary, of trials under DSM/QAC purview. The timing of the DSM/QAC review is prior to the annual IRB review. Finally, in pursuing its institutional mandate to provide real-time governance of the conduct of early-phase clinical trials, DSM/QAC will also assess Phase I studies for dose-limiting toxicities after each cohort, before dose escalation, and semiannually. DSM/QAC meets monthly and requires a quorum of three members. For calendar year 2009, 129 actions occurred at DSM/QAC meetings. Of these, 93 were annual reviews of protocols, 9 were safety reviews, 13 were reviews of responses from principal investigators to previous queries from DSM/QAC, and 12 were reviews of internal safety reviews or IRB conducted audits, with two protocols suspended as a result (counted as distinct actions). Of the 93 annual reviews, 78 were approved for continuance;12 remained open but had corrective actions prescribed;and 3 were referred for consideration of closure by the Clinical Research Committee, all with poor accruals.

Public Health Relevance

The conduct of clinical trials, particularly those sponsored by UMGCC with funding from the Cancer Center Support Grant (CCSG), requires assurance of quality and safety on a continuing basis to participants. DSM/QAC is the means for that to be accomplished according to an organized plan approved by NCI in its latest iteration on June 23, 2009, and formulated in response to the prior UMGCC CCSG review in 2008. DSM/QAC function is therefore central to the quality execution of sponsored clinical research at UMGCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA134274-06
Application #
8545700
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
6
Fiscal Year
2013
Total Cost
$57,267
Indirect Cost
$28,336
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19
Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63
Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :
Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546
Kerr, Candace; Adhikary, Gautam; Grun, Daniel et al. (2018) Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma. Mol Carcinog 57:3-11
Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813
Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423

Showing the most recent 10 out of 257 publications